Stock of The Day: Orient Paper Inc (NASDAQ:ORPN) Sentiment Worsened, Despite Downtrend

November 22, 2016 - By Nellie Frank   ·   0 Comments

Stock of The Day: Orient Paper Inc (NASDAQ:ORPN) Sentiment  Worsened,  Despite Downtrend

Sentiment for Orient Paper Inc (NASDAQ:ORPN)

Orient Paper Inc (NASDAQ:ORPN) institutional sentiment increased to 0.67 in 2016 Q2. Its up 0.07, from 0.6 in 2016Q1. The ratio is more positive, as 6 investment professionals started new or increased holdings, while 10 reduced and sold positions in Orient Paper Inc. The investment professionals in our partner’s database now have: 1.73 million shares, down from 2.74 million shares in 2016Q1. Also, the number of investment professionals holding Orient Paper Inc in their top 10 holdings was flat from 0 to 0 for the same number . Sold All: 2 Reduced: 8 Increased: 1 New Position: 5.

Bioblast Pharma Ltd is an Israel development-stage biopharmaceutical company. The company has a market cap of $25.08 million. The Firm is focused on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic and metabolic diseases. It currently has negative earnings. It focuses on therapeutic platforms that offer solutions for several diseases that share a common pathophysiological mechanism, which are the functional changes that accompany a particular syndrome or disease.

The stock closed at $1.53 during the last session. It is down 39.04% since April 20, 2016 and is downtrending. It has underperformed by 43.60% the S&P500.

According to Zacks Investment Research, “Bio Blast Pharma Ltd. is a clinical-stage biotechnology company. It engages in developing therapies for patients with rare and ultra-rare genetic diseases. Bio Blast products include Cabaletta to treat oculopharyngeal muscular dystrophy, Machado Joseph disease or SCA3, and Kennedy’s disease or SBMA; BBrm to treat diseases caused by nonsense mutation; and mPRT to treat mitochondrial protein deficiency diseases. The Company offers its products to the healthcare and medical industries. Bio Blast Pharma Ltd. is headquartered in Tel Aviv, Israel.”

Knoll Capital Management Lp holds 0.13% of its portfolio in Bioblast Pharma Ltd for 250,970 shares. Sabby Management Llc owns 830,253 shares or 0.07% of their US portfolio. Moreover, Visium Asset Management Lp has 0.01% invested in the company for 50,833 shares. The California-based Blackrock Fund Advisors has invested 0% in the stock. Blackrock Investment Management Llc, a New Jersey-based fund reported 1,255 shares.#img1#

Bioblast Pharma Ltd (NASDAQ:ORPN) Ratings Coverage

Ratings analysis reveals 100% of Bio Blast Pharma’s analysts are positive. Out of 3 Wall Street analysts rating Bio Blast Pharma, 3 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $6 while the high is $25. The stock’s average target of $19.25 is 1158.17% above today’s ($1.53) share price. ORPN was included in 5 notes of analysts from August 24, 2015. The firm earned “Buy” rating on Wednesday, December 9 by TH Capital. The stock of Bioblast Pharma Ltd (NASDAQ:ORPN) has “Buy” rating given on Monday, August 24 by Roth Capital. Zacks upgraded it to “Hold” rating and $6 target price in Tuesday, August 25 report. Rodman & Renshaw initiated the shares of ORPN in a report on Thursday, January 28 with “Buy” rating. The rating was maintained by Roth Capital with “Buy” on Wednesday, December 9.

ORPN Company Profile

Bio Blast Pharma Ltd. (BioBlast), incorporated on January 22, 2012, is a development-stage biopharmaceutical company. The Firm is focused on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic and metabolic diseases. It focuses on therapeutic platforms that offer solutions for several diseases that share a common pathophysiological mechanism, which are the functional changes that accompany a particular syndrome or disease. It also focuses on diseases with severe and debilitating manifestations. The Firm has several drug candidates in clinical or preclinical development targeting neuromuscular/central nervous system (CNS) and mitochondrial diseases. The Company’s drug candidates include Trehalose IV Solution, BB-FA (Bioblast-Friedreich’s ataxia) and BBrm-02. The Company’s product candidate platforms include Protein Stabilizing Platform, Read-through Platform and Mitochondrial Protein Replacement Platform.

More recent Bioblast Pharma Ltd (NASDAQ:ORPN) news were published by: Marketwatch.com which released: “/quotes/zigman/3870025/realtime” on August 02, 2014. Also 247Wallst.com published the news titled: “Bio Blast Pharma Explodes on Positive Results” on March 16, 2016. Quotes.Wsj.com‘s news article titled: “News Bioblast Pharma Ltd.ORPN” with publication date: July 27, 2014 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Nellie Frank


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>